Gelsolin is the fourth most abundant protein in the body and its depletion in the blood has been found in multiple sclerosis (MS) patients. How gelsolin affects the MS brain has not been studied. We found that while the secreted form of gelsolin (pGSN) decreased in the blood of experimental autoimmune encephalomyelitis (EAE) mice, pGSN concentration increased in the EAE brain. Recombinant human pGSN (rhp-GSN) decreased extracellular actin and myeloperoxidase activity in the brain, resulting in reduced disease activity and less severe clinical disease, suggesting that gelsolin could be a potential therapeutic target for MS.
Multiple sclerosis (MS) is the leading cause of non-traumatic neurological disability in young adults (Noseworthy et al., 2000) . While the etiology of MS remains unknown, it is characterized by inflammatory demyelinating plaques in the CNS (Bruck, 2005; Frohman et al., 2006; Imitola et al., 2006; Noseworthy et al., 2000) . A multitude of inflammatory factors has been investigated in MS, but relatively little is known about whether gelsolin (GSN), the fourth most abundant protein in the human body (Smith et al., 1987) , has a role in MS.
Gelsolin is the first and most widely expressed member of a family of actin-severing proteins in humans (Yin and Stossel, 1979) . Gelsolin is not only mainly produced from the muscle tissue but also expressed in the human central nervous system (Kwiatkowski et al., 1988; Tanaka et al., 1993) . It is involved in actin homeostasis, cell exocytosis, cell motility, phagocytosis, apoptosis, platelet formation and activation (Lee and Galbraith, 1992; Osborn et al., 2007; Silacci et al., 2004) . It has intracellular and secreted (termed pGSN) forms in the human body, which are structurally similar but not identical (Yin et al., 1984) . Both forms are from the same gene on the 9th chromosome, but the secreted form differs from the intracellular form by a 25-amino acid signaling peptide and the presence of a disulfide bond between cysteine residues at positions 188 and 201 (Wen et al., 1996; Yin et al., 1984) .
While a decrease of total gelsolin level in the blood was found in multiple sclerosis patients (Kulakowska et al., 2010) , it is yet unknown how multiple sclerosis affects secreted gelsolin in the brain (Yin et al., 1984) , and whether modulating gelsolin levels could have a therapeutic benefit for multiple sclerosis. Therefore, we aimed to evaluate the effects of neuroinflammation on the levels of pGSN in the brain in a mouse model of multiple sclerosis (experimental autoimmune encephalomyelitis [EAE] ) and to determine whether gelsolin has a therapeutic role for EAE/MS.
Materials and methods

EAE induction
All experimental protocols were approved by the Institutional Animal Care and use Committee of Massachusetts General Hospital. 111 SJL female mice 6-10 weeks old (Jackson Laboratories, Bar Harbor,
